ED-SCLC: RT yields OS, CSS benefit in chemotreated patients

  • Zhang R & al.
  • Cancer Manag Res
  • 01.01.2018

  • von Kelli Whitlock Burton
  • Studien – kurz & knapp
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Radiation therapy (RT) improved OS and cancer-specific survival (CSS) for patients with extensive-disease small cell lung cancer (ED-SCLC), but only for those who had also received chemotherapy.

Why this matters

  • Data on the benefit of RT in ED-SCLC are lacking.

Study design

  • 6812 patients with ED-SCLC from the Surveillance, Epidemiology, and End Results registry.
  • Propensity score matching (PSM) of 4212 patients, half with RT and half without.
  • Funding: National Science Foundation of China.

Key results

  • After PSM, RT significantly improved OS in patients with metastases in bone (HR, 0.85; 95% CI, 0.72-0.99), liver (HR, 0.68; 95% CI, 0.56-0.81), and lung (HR, 0.61; 95% CI, 0.49-0.76), but not the brain (HR, 0.91; 95% CI, 0.74-1.12).
  • OS improvement only in patients who received chemotherapy (Pinteraction<.01>
  • RT was most beneficial to patients with only lung metastases (7.0 vs 12.0 months for OS and CSS) and those with M1a with (6.0 vs 11.0 months for OS and 7.0 vs 11.0 months for CSS) and without (7.0 vs 12.0 months for OS and 9.0 vs 13.0 months for CSS) effusion.

Limitations

  • No data on metastatic sites other than bone, brain, lung, and liver.